# EDGAR Filing Document

**Accession Number:** 0001279695
**File Stem:** 0001279695-25-000006
**Filing Date:** 2025-11
**Character Count:** 7215
**Document Hash:** 3f45725d6108d71af566940181dec604
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001279695-25-000006.hdr.sgml**: 20251117

**ACCESSION NUMBER**: 0001279695-25-000006

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251114

**ITEM INFORMATION**: Changes in Registrant's Certifying Accountant

**FILED AS OF DATE**: 20251117

**DATE AS OF CHANGE**: 20251114

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** UNIVERSAL BIOSENSORS INC
- **CENTRAL INDEX KEY:** 0001279695
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 980424072
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-52607
- **FILM NUMBER:** 251488926

**BUSINESS ADDRESS:**
- **STREET 1:** 1 CORPORATE AVENUE
- **STREET 2:** ROWVILLE
- **CITY:** VICTORIA
- **STATE:** C3
- **ZIP:** 3178
- **BUSINESS PHONE:** 613-921-9000

**MAIL ADDRESS:**
- **STREET 1:** 1 CORPORATE AVENUE
- **STREET 2:** ROWVILLE
- **CITY:** VICTORIA
- **STATE:** C3
- **ZIP:** 3178

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549** 

**FORM 8-K** 

**CURRENT REPORT** 

**PURSUANT TO SECTION 13 OR 15(D)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

**Date of report (Date of earliest event reported) November 14, 2025**

**Universal Biosensors, Inc.** 

**(Exact Name of Registrant as Specified in Its Charter)** 

---

| | | | |
|:---|:---|:---|:---|
| **Delaware** | **000-52607** | **98-0424072** | **98-0424072** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** | **(IRS Employer**<br> **Identification No.)** |
| **1 Corporate Avenue**<br> **Rowville, 3178, Victoria**<br> **Australia** | **1 Corporate Avenue**<br> **Rowville, 3178, Victoria**<br> **Australia** |  | **Not Applicable** |
| **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**+61 3 9213 9000** 

**(Registrant's Telephone Number, Including Area Code)** 

**Not Applicable** 

**(Former Name or Former Address, if Changed Since Last Report)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

---

| | | |
|:---|:---|:---|
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  |
| ☐ | ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 4.01.** **Changes in Registrant's Certifying Accountant**

On November 14, 2025, PricewaterhouseCoopers ("PwC") resigned as the independent registered public accounting firm of Universal Biosensors, Inc. (the "Company"). A new independent accountant has not been engaged as the Company is ceasing operations, has entered into receivership, and intends to promptly deregister its securities.<br>

PwC's report on the Company's financial statements as of and for the fiscal years ended December 31, 2024 and 2023 did not contain any adverse opinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope, or accounting principles, except that PwC's report for the fiscal year ended December 31, 2024 included an explanatory paragraph indicating that there was substantial doubt about the Company's ability to continue as a going concern.

During the fiscal years ended December 31, 2024 and 2023 and the subsequent interim period through November 14, 2025, there were (i) no "disagreements" (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and PwC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of PwC, would have caused PwC to make reference to the subject matter of the disagreement in its reports on the Company's consolidated financial statements and (ii) no "reportable events" (as that term is defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions).

The Company provided PwC with a copy of this Current Report on Form 8-K and requested that PwC furnish to the Company a letter addressed to the United States Securities and Exchange Commission ("SEC") stating whether or not PwC agrees with the above statements and, if not, stating the respects in which it does not agree. A copy of PwC's letter to the SEC, dated November 14, 2025, is attached as Exhibit 16.1 to this Current Report on Form 8-K.

**Item 9.01.** **Financial Statements and Exhibits.** 

**(d)** **Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibits** |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **UNIVERSAL BIOSENSORS, INC.** | **UNIVERSAL BIOSENSORS, INC.** |
| Date: November 14, 2025 | By: | /s/ Peter Mullin  |
|  |  | Peter Mullin |
|  |  | CEO & Corporate Secretary |

---

------

## Exhibit 16.1

------

November 14, 2025

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Commissioners:

We have read the statements made by Universal Biosensors, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Universal Biosensors, Inc. dated November 14, 2025. We agree with the statements concerning our Firm contained therein.

Very truly yours,

/s/PricewaterhouseCoopers

Melbourne, Australia

Attachment

------